TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Alexion Pharmaceuticals to Acquire Achillion in $930 Million Deal
Play
INVESTING

Alexion to Buy Portola for $18 a Share, or $1.41 Billion

PRESS RELEASES

Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting

PRESS RELEASES

INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether The Following Mergers Are Fair To Shareholders; Investors Are Encouraged To Contact The Firm

PRESS RELEASES

U.S. Centers For Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement For Portola Pharmaceuticals' Andexxa® For Third Year

PRESS RELEASES

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Portola Pharmaceuticals, Inc. - PTLA

PRESS RELEASES

SHAREHOLDER ALERT: WeissLaw LLP Investigates Portola Pharmaceuticals, Inc.

PRESS RELEASES

Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast And Conference Call Following Agreement To Be Acquired By Alexion

PRESS RELEASES

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Portola Pharmaceuticals, Inc.

PRESS RELEASES

Moore Kuehn Encourages TORC, STML, KLXE, And PTLA Investors To Contact Law Firm

PRESS RELEASES

Portola Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Sale Of Portola Pharmaceuticals, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm

PRESS RELEASES

Shareholder Alert: Ademi & O'Reilly, LLP Investigates Whether Portola Pharmaceuticals, Inc. Has Obtained A Fair Price In Its Sale To Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals to Acquire Achillion in $930 Million Deal
INVESTING

Alexion to Buy Portola for $18 a Share, or $1.41 Billion

PRESS RELEASES

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PRESS RELEASES

Portola Pharmaceuticals To Announce First Quarter 2020 Financial Results On Monday, May 11, 2020

PRESS RELEASES

Portola Pharmaceuticals Announces The Establishment Of A Permanent J-code For Andexxa By The Centers For Medicare & Medicaid Services, Effective July 1, 2020

PRESS RELEASES

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PRESS RELEASES

Portola Pharmaceuticals Announces Proactive Steps Supporting Public Health Efforts To Combat Coronavirus (COVID-19)

PRESS RELEASES

Portola Pharmaceuticals Announces Results Demonstrating Andexxa® Was Associated With Lowest Rate Of Mortality In Patients With Multiple Types Of Factor Xa Inhibitor-Related Bleeds

PRESS RELEASES

PORTOLA 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuits Against Portola Pharmaceuticals, Inc. - PTLA

PRESS RELEASES

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That A Class Action Lawsuit Has Been Filed Against Portola Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm

PRESS RELEASES

PORTOLA 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuits Against Portola Pharmaceuticals, Inc. - PTLA

PRESS RELEASES

PTLA Final Deadline Monday: Rosen, A Globally Recognized Firm, Reminds Portola Pharmaceuticals, Inc. Investors Of Important March 16th Deadline In Securities Class Action - PTLA

PRESS RELEASES

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That A Class Action Lawsuit Has Been Filed Against Portola Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm

PRESS RELEASES

PTLA DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Portola Pharmaceuticals Inc. Investors With Losses Exceeding $100K Of Class Action And Lead Deadline: March 16, 2020

Mad Money Opening Bell Lead
JIM CRAMER

15 Years: Cramer's 'Mad Money' Recap (Friday 3/6/20)